21-Jan-2010 - Novartis International AG

Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS) is a unique project, bringing together top scientists from academic institutions with a wide range of expertise, and partnering them with nearly all major global drugs companies including AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Orion, Pfizer, Roche, Servier and Wyeth.

Other academic institutions involved are: Karolinska Institutet (Sweden), The University of Cambridge (United Kingdom), Central Institute of Mental Health (Germany), CSIC (Spain), the University of Manchester (United Kingdom) and the Bar Ilan University (Israel). A further two pharmaceutical small and medium-sized enterprises (SME), deCODE (Iceland) and Psynova (United Kingdom) will contribute to the success of NEWMEDS, while the SME GABO:mi (Germany) will be managing the project.

With a wealth of new knowledge and research findings related to schizophrenia and depression emerging every year, it has been hard to take these findings from the bench to the clinic. The researchers believe there to be three major bottlenecks that are holding the field back: a lack of accurate animal models to guide the drug discovery, a lack of tools and tests in healthy volunteers that can provide early indication of efficacy; and the reliance of clinical trials on symptom-based Diagnostic and Statistical Manual categories which inevitably leads to biologically heterogeneous groups of patients. NEWMEDS aims to overcome these limitations with a novel approach to drug discovery and strong collaboration within the consortium.

The main objective of NEWMEDS is to develop new models and methods to enable novel treatments for schizophrenia and depression. The project will focus on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia. The project will develop the hardware and analysis techniques to apply brain imaging, especially MRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication – trials that may require fewer patients and give faster results.

Facts, background information, dossiers
  • United Kingdom
  • Sweden
  • Spain
  • Servier
  • Roche
  • Pfizer
  • Orion
  • Novartis
  • Lundbeck
  • King's College London
  • Karolinska Institutet
  • Janssen Pharmaceutica
  • Iceland
  • GlaxoSmithKline
  • Germany
  • AstraZeneca
More about Novartis
More about Servier
More about Orion
  • News

    Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program

    Selvita S.A. announced that its collaboration with Orion Corporationon SEL103 program, for the symptomatic treatment of Alzheimer’s disease has reached the main research milestone and that the jointly discovered molecules from two different chemical families will progress into further pre-c ... more

    Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)

    Orion Corporation has received information that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of marketing authorisation for  dexdor® (dexmedetomidine), a new intensive care sedative.T ... more

    Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program

    Selvita sp. z o.o. and Orion Corporation from Espoo, Finland announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders. Selvita will be respon ... more

  • Companies

    Orion Diagnostica Oy

    Orion Diagnostica Oy is a biomedical company belonging to the Orion Group, the leading health-care company in Finland. Established in 1974, Orion Diagnostica specialises in rapid and easy-to-use clinical diagnostic and hygiene-monitoring products aimed at enhancing the quality and effective ... more

    Orion Corporation

    Orion Corporation is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. In 2006, Orion Corporation generated sales of EUR 641.1 million, invested EUR 84.1 million in research and development and employed approximately 3,060 people. Orio ... more

    Orion Pharma GmbH

    People are important to us. Our goal is to enable patients with effective preparations to achieve a better quality of life. In order to achieve this, we rethink all processes with regard to their long-term effects, taking a path between theoretically feasible and human meaningful. Respect f ... more

More about GSK
More about Wyeth
More about Eli Lilly
More about Karolinska Institutet
More about deCODE genetics
  • News

    Predicting the probability of death

    Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts  the time to all-cause death better than traditional risk factors. In a paper published in Communications Biology, scientists from deCODE genetics, a subsidiary of Amgen, ... more

    GENALICE and deCODE Genetics enter into a partnership for population wide genomic analysis

    GENALICE announced it is partnering with deCODE Genetics to facilitate the large-scale testing of its unique DNA data processing software solution, GENALICE MAP. After a first successful round of evaluating GENALICE MAP on speed and quality, both parties agreed to extend the evaluation to i ... more

    Scientists present the largest-to-date genetic snapshot of Iceland 1000 years ago

    Scientists at deCODE genetics have completed the largest study of ancient DNA from a single population ever undertaken. Analyzing mitochondrial DNA, which is passed from mother to offspring, from 68 skeletal remains, the study provides a detailed look at how a contemporary population differ ... more

  • Companies

    deCODE genetics

    deCODE is a biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health ... more

More about Lundbeck
  • News

    Genmab Reaches Second Milestone in Lundbeck Collaboration

    Genmab A/S announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders ... more

    Genmab announces progress with Lundbeck collaboration

    Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders o ... more

    Lundbeck and Proximagen Sign Strategic Partnership Agreement

    H. Lundbeck A/S  and Proximagen Group plc announced that they have entered into a Strategic Partnership Agreement.  The Agreement is designed to formalise a partnership between the two companies, a partnership in which Lundbeck and Proximagen will jointly apply their expertise in CNS drug d ... more

  • Companies

    Lundbeck España S.A.


    Lundbeck Pharmaceuticals Italy S.p.A. (LUPI)

    Lundbeck Pharmaceuticals Italy is an FDA inspected manufacturer of proprietary APIs and cGMP intermediates for the pharmaceutical, veterinary and life science industries. All our products are manufactured under cGMP's. LUPI offers contract manufacturing services to many large multinati ... more

    Lundbeck AG

    We encourage creative thinking and proactive action in order to sustainably satisfy customers with clearly differentiated value propositions and services. more

More about Pfizer
More about King's College London
More about Roche
  • News

    Start-up Inflazome Announces Acquisition by Roche

    Inflazome announced that it has closed a share purchase agreement with Roche  in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.  I ... more

    Roche acquires Stratos Genomics

    Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequen ... more

    Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

    Roche announced that it are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Servi ... more

  • Companies

    Roche Austria GmbH

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more

    Roche Deutschland Holding GmbH


More about University of Cambridge
  • News

    Scientists identify the cause of Alzheimer’s progression in the brain

    For the first time, researchers have used human data to quantify the speed of different processes that lead to Alzheimer’s disease and found that it develops in a very different way than previously thought. Their results could have important implications for the development of potential tre ... more

    Scientists identify 160 new drugs that could be repurposed against COVID-19

    Cambridge scientists have identified 200 approved drugs predicted to work against COVID-19 - of which only 40 are currently being tested in COVID-19 clinical trials. In a study published today in Science Advances, a team led by researchers at the University of Cambridge's Milner Therapeutic ... more

    On the hunt for the roots of cancer

    Red2Onco, an innovative genetic mouse model, allows to detect the very initial steps that lead to cancer development. Red2Onco’s multi-colour labelling system allows to trace intestinal tumour development after the first oncogenic hit at the single cell level. The research carried out at IM ... more

  • Videos

    Fighting cancer: Animal research at Cambridge

    Animal research plays an essential role in our understanding of health and disease and in the development of modern medicine and surgical techniques. As part of our commitment to openness, this film examines how mice are helping the fight against cancer. It takes a in-depth look at the faci ... more

    Killer T Cell: The Cancer Assassin

    How does a Killer T Cell Kill its target?The new film captures the behaviour of cytotoxic T cells – the body’s ‘serial killers’ – as they hunt down and eliminate cancer cells before moving on to their next target. more

    The Super-Resolution Revolution

    Cambridge scientists are part of a resolution revolution. Building powerful instruments that shatter the physical limits of optical microscopy, they are beginning to watch molecular processes as they happen, and in three dimensions. Here, Professor Clemens Kaminski describes how a new era o ... more

More about AstraZeneca
More about University of Manchester
  • News

    New antibiotics by gene editing

    Scientists have discovered a new route to produce complex antibiotics exploiting gene editing to re-programme pathways to future medicines urgently required to combat antimicrobial resistance, treat neglected diseases and prevent future pandemics. Researchers from The University of Manchest ... more

    Protein closely linked to commonest cause of blindness

    An international team of scientists has identified a protein which is strongly linked to the commonest cause of blindness in developed countries when its levels are raised in the blood. The discovery is a major step forward in the understanding of age-related macular degeneration, which aff ... more

    Unique new antiviral treatment made using sugar

    New antiviral materials made from sugar have been developed to destroy viruses on contact and may help in the fight against viral outbreaks. This new development from a collaborative team of international scientists shows promise for the treatment of herpes simplex (cold sore virus), respir ... more

More about Janssen Pharmaceutica
More about CSIC
More about Bar-Ilan University
More about Zentralinstitut für Seelische Gesundheit